Visceral fat
Also called: belly fat, intra-abdominal fat, central adiposity
Visceral fat is the fat that surrounds the organs deep inside the abdomen. It is metabolically active and behaves like an organ in itself, releasing inflammatory chemicals and influencing insulin sensitivity. Higher visceral fat is associated with type 2 diabetes, heart disease and stroke risk, independent of overall body weight. People can have high visceral fat at a normal BMI.
Visceral fat vs subcutaneous fat
Subcutaneous fat sits under the skin. You can pinch it. It is mostly cosmetic and metabolically calmer. Visceral fat sits behind the abdominal wall, wrapped around organs like the liver, intestines and pancreas. You cannot pinch it. It is highly metabolically active. The two store fat differently and respond differently to diet and exercise.
Why visceral fat is the harmful kind
- Releases pro-inflammatory cytokines like TNF-alpha and IL-6 that drive low-grade inflammation throughout the body.
- Drains directly into the portal vein and liver, increasing the liver's exposure to free fatty acids and hormones.
- Strongly linked with insulin resistance, even in people with otherwise-normal BMI.
- Independently associated with cardiovascular disease, type 2 diabetes, certain cancers, and dementia risk.
- More responsive to cortisol, which is why chronic stress preferentially adds belly fat.
How to measure it without a scan
Gold-standard measurement is MRI or DEXA scanning. These are not routine in NHS care unless clinically indicated. Practical at-home proxies have decent evidence:
- Waist circumference. Measure at the level of the belly button, exhale, do not suck in. Commonly used cut-offs (from IDF and earlier NICE guidance) put lower-risk under 80 cm for women and under 94 cm for men, and high-risk above 88 cm and 102 cm. Current NICE NG246 favours waist-to-height ratio over fixed waist cut-offs.
- Waist-to-height ratio. Waist measurement divided by height. Below 0.5 is the target for most adults. Better predictor than BMI for visceral risk.
- Bioimpedance scales. Devices like InBody and decent home smart scales estimate visceral fat. Accuracy is moderate but useful for tracking trends in yourself.
What reduces visceral fat
- A modest calorie deficit. Even 5 to 10 percent total body weight loss preferentially shrinks visceral fat first.
- Strength training. Resistance training is associated with reduced body adiposity and improved insulin sensitivity and metabolic markers.
- Aerobic exercise. Moderate cardio is associated with lower visceral fat in trials, with greater reductions at higher weekly energy expenditure.
- Reducing ultra-processed food intake.
- Sleep. Less than 6 hours a night is independently associated with higher visceral fat.
- Limiting alcohol within UK guidelines (no more than 14 units a week, spread out, with several alcohol-free days).
Cortisol belly: what is real and what is not
Chronic stress and elevated cortisol do influence where the body stores fat, with a measurable bias toward visceral fat. The viral TikTok concept of cortisol belly is partly accurate (the mechanism is real) and partly oversold (most belly fat in most people is overall calorie balance, not isolated cortisol). Cortisol-targeted supplements have weak evidence. Sleep, stress management, exercise and food consistency cover most of what helps.
Common questions
- Can you have high visceral fat at a normal weight?
- Yes. The pattern is sometimes called TOFI (thin outside, fat inside). It is more common in people with sedentary lifestyles, low muscle mass, certain genetic backgrounds (South Asian populations are at higher risk), and post-menopausal women. Waist-to-height ratio is a better risk indicator than BMI in these cases.
- Do GLP-1 drugs reduce visceral fat?
- Yes, in clinical trials they reduce visceral fat preferentially. The SURPASS-3 MRI substudy of tirzepatide showed significant reduction in visceral adipose tissue volume versus comparator. The same is broadly true of semaglutide. This is one of the cardiovascular benefits beyond weight loss alone.
- How quickly can you lose visceral fat?
- Visceral fat tends to be the first to shrink during a calorie deficit. Trials show meaningful visceral fat reductions with sustained calorie restriction and exercise over weeks to months. Weight loss of 5 to 10 percent of starting body weight produces meaningful visceral reduction.
- Are spot exercises useful for belly fat?
- No. You cannot direct fat loss to a specific area through exercise. Sit-ups strengthen abdominal muscles but do not preferentially burn the fat covering them. Total energy balance and overall fitness are what matter for visceral fat reduction.
Sources
- Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines (Makki et al, 2013) (ISRN Inflammation (PMC))
- Visceral fat and metabolic inflammation: the portal theory revisited (Item & Konrad, 2012, Obes Rev) (Obesity Reviews (PubMed))
- Association of pericardial, intrathoracic, and visceral abdominal fat with CVD burden: Framingham Heart Study (Framingham Heart Study (PMC))
- NICE NG246 Overweight and obesity management: identifying and assessing central adiposity (waist-to-height ratio under 0.5) (NICE)
- Waist measurement and obesity: waist circumference cut-offs (men 94/102 cm, women 80/88 cm) (GPnotebook)
- Dose-response effects of exercise and caloric restriction on visceral adiposity: systematic review and meta-analysis of RCTs (British Journal of Sports Medicine (PMC))
- Change in sleep duration and visceral fat accumulation over 6 years in adults (Obesity (PubMed))
- Glucocorticoids and HPA axis regulation in the stress-obesity connection (visceral fat, glucocorticoid receptor density) (PMC review)
- Effect of tirzepatide vs insulin degludec on liver fat and abdominal adipose tissue (SURPASS-3 MRI substudy) (Lancet Diabetes & Endocrinology (PubMed))
- Body composition changes during weight reduction with tirzepatide in SURMOUNT-1 (DXA substudy) (Diabetes Obes Metab (PubMed))
- Obesity and dyslipidemia in South Asians (higher abdominal/visceral adiposity at lower BMI) (Nutrients (PMC))
- Alzheimer disease pathology and neurodegeneration in midlife obesity (visceral fat and AD pathology) (Aging and Disease (PMC))
- A new approach to quantify visceral fat via BIA and ultrasound compared to MRI (BIA limitations) (International Journal of Obesity (PMC))